Publications by authors named "Marcus Burns"
Background: SAPIEN3 (S3) is a ubiquitous redo-transcatheter aortic valve (TAV) replacement alternative for degenerated Evolut valves, but S3 sizing for S3-in-Evolut remains unclear. We sought to compare the impact of in vivo computed tomography (CT)-sizing on redo-TAV feasibility for S3-in-Evolut with traditional bench-sizing.
Methods: CT scans of 290 patients treated using Evolut R/PRO/PRO+ between July 2015 and December 2021 were analyzed.
Background: Our aim was to assess the feasibility of repeat transcatheter aortic valve (TAV) replacement for degenerated Sapien3 (S3) prostheses by simulating subsequent implantation of S3 or Evolut, using in vivo computed tomography-based sizing and the impact on coronary and patient-prosthesis mismatch risks.
Methods: Computed tomography scans from 356 patients with prior S3 TAV replacement implantation were analyzed. The in vivo sizing for second TAV based on averaged area of 3 levels of outflow, mid (narrowest) and inflow, was compared with in vitro recommendations, that is, same size as index S3 for second S3 and 1 size larger for Evolut.
Deformation of transcatheter heart valves with mitral valve-in-valve.
EuroIntervention
December 2023
Background: The use of oversizing in mitral valve-in-valve (MViV) procedures can lead to non-uniform expansion of transcatheter heart valves (THV). This may have implications for THV durability.
Aims: The objective of this study was to assess the extent and predictors of THV deformation in MViV procedures.
Article Synopsis
- TAVI is an effective treatment for severe aortic stenosis, but there's room for better technology focused on improving flow and durability.
- This study tested the safety and feasibility of the DurAVR biomimetic transcatheter heart valve in patients with symptomatic severe aortic stenosis in a first-in-human trial.
- Results showed successful implantation in all cases with minimal complications, favorable hemodynamics at 30 days and 1 year, and restoration of healthy blood flow patterns, indicating promising potential for the DurAVR valve.
Prospective investigations for the frequency of hypoattenuated leaflet thickening (HALT) and its clinical implications in transcatheter aortic valve implantation (TAVI) patients are limited. We initiated a prospective screening program of TAVI patients for HALT beginning in July 2015. Eligible patients were evaluated with gated, contrast-enhanced multidetector computed tomography within 30 days of TAVI, and examined for HALT and clinical outcomes.
View Article and Find Full Text PDF